ALX Oncology (ALXO)

• Market cap: $89.7M
• 1 day: -7.10%
• 5 days: -4.49%
• 1 month: 14.09%
• 3 months: -9.09%
• 6 months: -71.09%
• Year to date: -88.32%
• 1 year: -88.73%
• 5 years: -94.33%
• 10 years: -94.33%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Employees: 89

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

487% more call options, than puts

Call options by funds: $364K | Put options by funds: $62K

90% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 21

8.18% less ownership

Funds ownership: 94.49% [Q2] → 86.31% (-8.18%) [Q3]

16% less funds holding

Funds holding: 110 [Q2] → 92 (-18) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

50% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 36

72% less capital invested

Capital invested by funds: $297M [Q2] → $83.1M (-$214M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 18% upside
• Avg. target: $13.50 694% upside
• High target: $25 1,371% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target	18% upside $2	Hold Downgraded	19 Dec 2024
HC Wainwright & Co. Swayampakula Ramakanth 29% 1-year accuracy 51 / 173 met price target	1,371% upside $25	Buy Reiterated	18 Dec 2024